흑색종 치료제 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 약물 유형별, 지역별, 부문별 예측(2023-2030년)

Melanoma Therapeutics Market Size, Share & Trends Analysis Report By Product (Chemotherapy, Immunotherapy), By Drug Type (Branded Drugs, Generic Drugs), By Region, And Segment Forecasts, 2023 - 2030

US $ 5,950 ￦ 8,362,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,768,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,579,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

흑색종 치료제 시장의 성장과 동향:

Grand View Research, Inc.의 최신 보고서에 따르면 흑색종 치료제 세계 시장 규모는 2030년까지 109억 8,000만 달러에 달할 것으로 예상되며 2023년부터 2030년까지 10.3%의 CAGR을 기록할 것으로 전망되고 있습니다.

흑색종, 피부암, 피부 알레르기 등 만성 질환의 발생률 증가는 시장의 중요한 촉진요인입니다.

CDC에 따르면 2013년 71,943명 이상이 흑색종에 걸렸다고 합니다. 미국암협회는 2017년에는 이 숫자가 87,100명으로 증가할 것으로 예측하고 있으며, 예측 기간 동안 흑색종 치료제의 필요성을 강조하고 있습니다.

FDA 승인 증가와 효능이 향상된 새로운 치료제의 도입도 성장 기회를 제공할 것으로 예상되며, 2011년부터 2016년까지 6년간 옵디보, 야보이, 코텔릭, 젤보라프, 키트루다, 메퀴니스트, 타핀라, 임리직 등 8개의 생물학적 흑색종 치료제로 승인되었습니다.

기업들은 기존 제품의 새로운 적응증을 발견하고 혁신적인 분자를 개발하기 위해 다양한 연구개발 활동을 하고 있습니다. 예를 들어, 2014년 9월, 미국 FDA는 특허 의약품 키트루다(Merck)를 전이성 흑색종 치료제로 승인하여 치료 적응증을 확대했습니다. 이 약은 당초 비소세포폐암 치료제로 승인되었습니다.

또한 미국, 유럽, 아시아태평양의 많은 제약회사들이 새로운 생물학적 제제 개발에 주력하고 있습니다. 예를 들어, 다이이찌산쿄(Daiichi Sankyo Corporation)는 2017년 3월 공동연구를 통한 신약 개발을 촉진하기 위한 공동 신약개발 프로젝트인 TaNeDS(Take a New Challenge for Drug discovery)를 발표했습니다. 또한 AgonOX, Inc.와 전략적 연구제휴를 체결하고 면역 및 암 분야의 신규 면역치료제 개발에 힘쓰고 있습니다. 예측 기간 동안 신규 제품이 승인되면 시장 성장을 촉진할 것으로 예상됩니다.

흑색종 치료제 시장 보고서 하이라이트

• 표적치료제 부문은 부작용이 적고 효율성이 높다는 장점으로 인해 예측 기간 동안 11.9%의 유리한 성장세를 보일 것으로 예상됩니다.
• 특허로 인한 독점권으로 2022년 브랜드 의약품의 업계 점유율은 91.33%로 압도적입니다.
• 옵디보와 코텔릭과 같은 생물학적 제제는 채택 증가와 치료 효과 향상 등의 장점으로 인해 예측 기간 동안 유리한 성장을 보일 것으로 예상됩니다.
• 야보이의 특허는 미국에서는 2022년, 유럽에서는 2020년에 만료됩니다. 이에 따라 신규 진입 기업에게 성장 기회를 가져다 줄 것으로 기대됩니다.
• 아시아태평양은 예측 기간 동안 11.6%의 유리한 CAGR을 보일 것으로 예상됩니다.
• 주요 시장 진입 기업들은 흑색종 치료용 신약 발견 및 개발을 위한 연구개발 노력을 강화하고 있습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 흑색종 치료제 시장 변수, 동향, 범위

• 시장 계통 전망
  • 상부 시장 전망
  • 관련/부수 시장 전망
• 보급과 성장 전망 매핑
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 흑색종 치료제 시장 분석 툴
  • 업계 분석 - Porter's Five Forces 분석
  • PESTEL 분석

제4장 흑색종 치료제 : 제품 추정·동향 분석

• 흑색종 치료제 시장 : 중요한 포인트
• 흑색종 치료제 시장 : 동향과 시장 점유율 분석, 2022년 및 2030년
• 화학요법
• 면역요법
• 표적요법
• 방사선 치료

제5장 흑색종 치료제 : 약제 유형 추정·동향 분석

• 흑색종 치료제 시장 : 중요한 포인트
• 흑색종 치료제 시장 : 동향과 시장 점유율 분석, 2022년 및 2030년
• 브랜드 의약품
• 제네릭 의약품

제6장 흑색종 치료제 시장 : 지역 추정·동향 분석

• 지역 전망
• 지역별 흑색종 치료제 시장 : 중요한 포인트
• 북미
  • 미국
  • 캐나다
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 스웨덴
  • 노르웨이
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 태국
  • 한국
• 라틴아메리카
  • 브라질
  • 멕시코
  • 아르헨티나
• 중동 및 아프리카
  • 사우디아라비아
  • 남아프리카공화국
  • 아랍에미리트
  • 쿠웨이트

제7장 경쟁 상황

• 주요 시장 진출 기업에 의한 최근의 동향과 영향 분석
• 회사/경쟁 분류
  • Bristol-Myers Squibb Company
  • AstraZeneca
  • Novartis AG
  • Merck & Co, Inc.
  • Amgen Inc.
  • F. Hoffman-La Roche Ltd.
  • Abbott Laboratories

ksm

영문 목차

영문목차

Melanoma Therapeutics Market Growth & Trends:

The global melanoma therapeutics market size is expected to reach USD 10.98 billion by 2030, registering a CAGR of 10.3% from 2023 to 2030, according to a new report by Grand View Research, Inc.. Increasing incidence of chronic diseases such as melanoma, skin cancer, and skin allergies is an important driver of the market.

According to the CDC, over 71,943 people were affected by melanoma in 2013. The American Cancer Society estimates that this number will go up to 87,100 in 2017, thus highlighting the need for melanoma drugs over the forecast period.

Increasing number of FDA approvals and the introduction of novel therapeutics with enhanced efficacy are also anticipated to present growth opportunities. Within a period of 6 years, i.e., from 2011 to 2016, around eight biologics have been approved for the treatment of this disease, which includes Opdivo, Yervoy, Cotellic, Zelboraf, Keytruda, Mekinist, Tafinlar, and Imlygic.

Companies are undertaking various R&D activities to find new indications for existing products and the development of innovative molecules. For instance, in September 2014, the U.S. FDA approved patented drug Keytruda (Merck & Co., Inc.) to treat metastatic melanoma, thereby extending the therapeutic application of its product. This drug was initially approved for the treatment of non-small cell lung cancer.

Furthermore, many pharmaceutical companies in the U.S., Europe, and Asia Pacific are focusing on the development of new biologics. For instance, in March 2017, Daiichi Sankyo Company, Limited announced a collaborative drug discovery project-Take a New Challenge for Drug discovery (TaNeDS)-to facilitate new drug development through collaborations. Moreover, it entered into a strategic research collaboration with AgonOX, Inc. to develop new immunotherapy drugs for the immuno-oncology segment. The approval of novel products over the forecast period is anticipated to boost the market growth.

Melanoma Therapeutics Market Report Highlights:

• Targeted therapy segment is expected to show lucrative growth of 11.9% over the forecast periodowing to benefits such as low adverse effects and higher efficiency
• Branded drugs held a dominant share of 91.33% in 2022 of the industry because of patent exclusivity
• Biologics, such as Opdivo and Cotellic, are expected to exhibit lucrative growth over the forecast period owing to increase adoption and advantages such as improved therapeutic effects
• The patent for Yervoy will expire in 2022 in the U.S. and in 2020 in Europe. This is expected to provide growth opportunities for new market entrants
• Asia Pacific is expected to exhibit lucrative CAGR of 11.6% over the forecast period
• Key market players are increasing R&D efforts for the discovery and development of novel drugs for the treatment of melanoma

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Product
  • 1.1.2. Drug type
  • 1.1.3. Regional scope
  • 1.1.4. Estimates and forecast timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives
  • 1.9.1. Objective 1
  • 1.9.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Drug type outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Melanoma Therapeutics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Market Dynamics
  • 3.3.1. Market drivers analysis
  • 3.3.2. Market restraints analysis
• 3.4. Melanoma Therapeutics Market Analysis Tools
  • 3.4.1. Industry Analysis - Porter's
    • 3.4.1.1. Supplier power
    • 3.4.1.2. Buyer power
    • 3.4.1.3. Substitution threat
    • 3.4.1.4. Threat of new entrant
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Technological landscape
    • 3.4.2.3. Economic landscape

Chapter 4. Melanoma Therapeutics: Product Estimates & Trend Analysis

• 4.1. Melanoma Therapeutics Market: Key Takeaways
• 4.2. Melanoma Therapeutics Market: Movement & Market Share Analysis, 2022 & 2030
• 4.3. Chemotherapy
  • 4.3.1. Chemotherapy market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.4. Immunotherapy
  • 4.4.1. Immunotherapy market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.5. Targeted Therapy
  • 4.5.1. Targeted therapy estimates and forecasts, 2018 to 2030 (USD Million)
• 4.6. Radiation Therapy
  • 4.6.1. Radiation therapy market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Melanoma Therapeutics: Drug Type Estimates & Trend Analysis

• 5.1. Melanoma Therapeutics Market: Key Takeaways
• 5.2. Melanoma Therapeutics Market: Movement & Market Share Analysis, 2022 & 2030
• 5.3. Branded Drugs
  • 5.3.1. Branded drugs market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.4. Generic Drugs
  • 5.4.1. Generic drugs market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Melanoma Therapeutics Market: Regional Estimates & Trend Analysis

• 6.1. Regional Outlook
• 6.2. Melanoma Therapeutics Market by Region: Key Takeaways
• 6.3. North America
  • 6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.3.2. U.S.
    • 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.3.3. Canada
    • 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 6.4. Europe
  • 6.4.1. UK
    • 6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4.2. Germany
    • 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4.3. France
    • 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4.4. Italy
    • 6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4.5. Spain
    • 6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4.6. Sweden
    • 6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4.7. Norway
    • 6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4.8. Denmark
    • 6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Japan
    • 6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5.2. China
    • 6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5.3. India
    • 6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5.4. Australia
    • 6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5.5. Thailand
    • 6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5.6. South Korea
    • 6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 6.6. Latin America
  • 6.6.1. Brazil
    • 6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6.2. Mexico
    • 6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6.3. Argentina
    • 6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 6.7. MEA
  • 6.7.1. Saudi Arabia
    • 6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7.2. South Africa
    • 6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7.3. UAE
    • 6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7.4. Kuwait
    • 6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
  • 7.2.1. Bristol-Myers Squibb Company
    • 7.2.1.1. Company overview
    • 7.2.1.2. Financial performance
    • 7.2.1.3. Product benchmarking
    • 7.2.1.4. Strategic initiatives
  • 7.2.2. AstraZeneca
    • 7.2.2.1. Company overview
    • 7.2.2.2. Financial performance
    • 7.2.2.3. Product benchmarking
    • 7.2.2.4. Strategic initiatives
  • 7.2.3. Novartis AG
    • 7.2.3.1. Company overview
    • 7.2.3.2. Financial performance
    • 7.2.3.3. Product benchmarking
    • 7.2.3.4. Strategic initiatives
  • 7.2.4. Merck & Co, Inc.
    • 7.2.4.1. Company overview
    • 7.2.4.2. Financial performance
    • 7.2.4.3. Product benchmarking
    • 7.2.4.4. Strategic initiatives
  • 7.2.5. Amgen Inc.
    • 7.2.5.1. Company overview
    • 7.2.5.2. Financial performance
    • 7.2.5.3. Product benchmarking
    • 7.2.5.4. Strategic initiatives
  • 7.2.6. F. Hoffman-La Roche Ltd.
    • 7.2.6.1. Company overview
    • 7.2.6.2. Financial performance
    • 7.2.6.3. Product benchmarking
    • 7.2.6.4. Strategic initiatives
  • 7.2.7. Abbott Laboratories.
    • 7.2.7.1. Company overview
    • 7.2.7.2. Financial performance
    • 7.2.7.3. Product benchmarking
    • 7.2.7.4. Strategic initiatives=

List of Tables

• Table 1 List of Abbreviation
• Table 2 North America melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
• Table 3 North America melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
• Table 4 North America melanoma therapeutics market, by region, 2018 - 2030 (USD Million)
• Table 5 U.S. melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
• Table 6 U.S. melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
• Table 7 Canada melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
• Table 8 Canada melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
• Table 9 Europe melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
• Table 10 Europe melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
• Table 11 Europe melanoma therapeutics market, by region, 2018 - 2030 (USD Million)
• Table 12 Germany melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
• Table 13 Germany melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
• Table 14 UK melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
• Table 15 UK melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
• Table 16 France melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
• Table 17 France melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
• Table 18 Italy melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
• Table 19 Italy melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
• Table 20 Spain melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
• Table 21 Spain melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
• Table 22 Sweden melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
• Table 23 Sweden melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
• Table 24 Norway melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
• Table 25 Norway melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
• Table 26 Denmark melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
• Table 27 Denmark melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
• Table 28 Asia Pacific melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
• Table 29 Asia Pacific melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
• Table 30 Asia Pacific melanoma therapeutics market, by region, 2018 - 2030 (USD Million)
• Table 31 China melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
• Table 32 China melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
• Table 33 Japan melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
• Table 34 Japan melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
• Table 35 India melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
• Table 36 India melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
• Table 37 Thailand melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
• Table 38 Thailand melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
• Table 39 South Korea melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
• Table 40 South Korea melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
• Table 41 Latin America melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
• Table 42 Latin America melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
• Table 43 Latin America melanoma therapeutics market, by region, 2018 - 2030 (USD Million)
• Table 44 Brazil melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
• Table 45 Brazil melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
• Table 46 Mexico melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
• Table 47 Mexico melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
• Table 48 Argentina melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
• Table 49 Argentina melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
• Table 50 Middle East and Africa melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
• Table 51 Middle East and Africa melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
• Table 52 Middle East and Africa melanoma therapeutics market, by region, 2018 - 2030 (USD Million)
• Table 53 South Africa melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
• Table 54 South Africa melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
• Table 55 Saudi Arabia melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
• Table 56 Saudi Arabia melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
• Table 57 UAE melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
• Table 58 UAE melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
• Table 59 Kuwait melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
• Table 60 Kuwait melanoma therapeutics market, by drug type, (USD Million) 2018 - 2030Report SummaryTable of ContentsSegmentationMethodologyRequest a FREE Sample Copy

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Product
  • 1.1.2. Drug type
  • 1.1.3. Regional scope
  • 1.1.4. Estimates and forecast timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives
  • 1.9.1. Objective 1
  • 1.9.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Drug type outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Melanoma Therapeutics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Market Dynamics
  • 3.3.1. Market drivers analysis
  • 3.3.2. Market restraints analysis
• 3.4. Melanoma Therapeutics Market Analysis Tools
  • 3.4.1. Industry Analysis - Porter's
    • 3.4.1.1. Supplier power
    • 3.4.1.2. Buyer power
    • 3.4.1.3. Substitution threat
    • 3.4.1.4. Threat of new entrant
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Technological landscape
    • 3.4.2.3. Economic landscape

Chapter 4. Melanoma Therapeutics: Product Estimates & Trend Analysis

• 4.1. Melanoma Therapeutics Market: Key Takeaways
• 4.2. Melanoma Therapeutics Market: Movement & Market Share Analysis, 2022 & 2030
• 4.3. Chemotherapy
  • 4.3.1. Chemotherapy market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.4. Immunotherapy
  • 4.4.1. Immunotherapy market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.5. Targeted Therapy
  • 4.5.1. Targeted therapy estimates and forecasts, 2018 to 2030 (USD Million)
• 4.6. Radiation Therapy
  • 4.6.1. Radiation therapy market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Melanoma Therapeutics: Drug Type Estimates & Trend Analysis

• 5.1. Melanoma Therapeutics Market: Key Takeaways
• 5.2. Melanoma Therapeutics Market: Movement & Market Share Analysis, 2022 & 2030
• 5.3. Branded Drugs
  • 5.3.1. Branded drugs market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.4. Generic Drugs
  • 5.4.1. Generic drugs market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Melanoma Therapeutics Market: Regional Estimates & Trend Analysis

• 6.1. Regional Outlook
• 6.2. Melanoma Therapeutics Market by Region: Key Takeaways
• 6.3. North America
  • 6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.3.2. U.S.
    • 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.3.3. Canada
    • 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 6.4. Europe
  • 6.4.1. UK
    • 6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4.2. Germany
    • 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4.3. France
    • 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4.4. Italy
    • 6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4.5. Spain
    • 6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4.6. Sweden
    • 6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4.7. Norway
    • 6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4.8. Denmark
    • 6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Japan
    • 6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5.2. China
    • 6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5.3. India
    • 6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5.4. Australia
    • 6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5.5. Thailand
    • 6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5.6. South Korea
    • 6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 6.6. Latin America
  • 6.6.1. Brazil
    • 6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6.2. Mexico
    • 6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6.3. Argentina
    • 6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 6.7. MEA
  • 6.7.1. Saudi Arabia
    • 6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7.2. South Africa
    • 6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7.3. UAE
    • 6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7.4. Kuwait
    • 6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
  • 7.2.1. Bristol-Myers Squibb Company
    • 7.2.1.1. Company overview
    • 7.2.1.2. Financial performance
    • 7.2.1.3. Product benchmarking
    • 7.2.1.4. Strategic initiatives
  • 7.2.2. AstraZeneca
    • 7.2.2.1. Company overview
    • 7.2.2.2. Financial performance
    • 7.2.2.3. Product benchmarking
    • 7.2.2.4. Strategic initiatives
  • 7.2.3. Novartis AG
    • 7.2.3.1. Company overview
    • 7.2.3.2. Financial performance
    • 7.2.3.3. Product benchmarking
    • 7.2.3.4. Strategic initiatives
  • 7.2.4. Merck & Co, Inc.
    • 7.2.4.1. Company overview
    • 7.2.4.2. Financial performance
    • 7.2.4.3. Product benchmarking
    • 7.2.4.4. Strategic initiatives
  • 7.2.5. Amgen Inc.
    • 7.2.5.1. Company overview
    • 7.2.5.2. Financial performance
    • 7.2.5.3. Product benchmarking
    • 7.2.5.4. Strategic initiatives
  • 7.2.6. F. Hoffman-La Roche Ltd.
    • 7.2.6.1. Company overview
    • 7.2.6.2. Financial performance
    • 7.2.6.3. Product benchmarking
    • 7.2.6.4. Strategic initiatives
  • 7.2.7. Abbott Laboratories.
    • 7.2.7.1. Company overview
    • 7.2.7.2. Financial performance
    • 7.2.7.3. Product benchmarking
    • 7.2.7.4. Strategic initiatives

관련자료